PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

• DOI: 10.1200/jco.2020.38.6_suppl.134
• Publication Date: 2020-02-19T16:59:57Z
• Authors: Johann S. De Bono; Karim Fizazi; Fred Saad; Neal D. Shore; Guilhem Roubaud; Mustafa Ozguroglu; Nicolas Penel; Nobuaki Matsubara; Niven Mehra; Giuseppe Procopio; Michael Paul Koli...; Kazuo Nishimura; Susan Feyerabend; Jae Young Joung; Nicholas J. Vogel...; Michael Anthony C...; Jinyu Kang; Christian Heinric...; Wenting Wu; Maha H. A. Hussain
• Keywords: Taxane; Enzalutamide; Olaparib

134 Background: Optimal sequencing of therapies for mCRPC is not established. In the Phase III PROfound study (NCT02987543), ola significantly prolonged radiographic progression-free survival (rPFS) vs physician’s choice new hormonal agent (pcNHA) in pts with and an alteration genes a direct or indirect role HRR. We report exploratory subgroup analyses by prior taxane (yes no). Methods: Men that had progressed on NHA were randomized to (tablets; 300 mg bid) pcNHA (enzalutamide abiraterone). Pts alterations BRCA1, BRCA2 ATM (Cohort A) ≥1 12 other prespecified HRR B). Stratification factors use measurable disease. rPFS was assessed blinded independent central review RECIST v1.1 + PCWG3. Results: Subgroup overall (OS) favored irrespective Cohort A, Cohorts A+B BRCA1 and/or CDK12 (Table). hazard ratio (HR) point estimates OS lower who received not, but 95% CIs overlapped pt numbers small so data should be interpreted caution. Conclusions: The benefit over gene generally status population. Clinical trial information: NCT02987543. [Table: see text]